Browsing Tag
biotech
31 posts
Is cloud infrastructure becoming biotech’s new competitive edge? How Absci’s cloud leap is shifting the R&D battleground
Is cloud compute now biotech’s real battleground? See why AI-powered platforms like Absci are making cloud infrastructure their secret weapon.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Theravance completes enrollment in Phase 3 CYPRESS trial for ampreloxetine in MSA-related nOH
Theravance completes Phase 3 enrollment for ampreloxetine in MSA-related nOH. Topline data expected in Q1 2026. Could this be a rare disease breakthrough?
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.
Quantum-Si secures $50m in registered direct offering to expand single-molecule protein sequencing platform
Quantum-Si Incorporated secures $50 million through a registered direct offering of common stock, bolstering its single-molecule proteomics platform.
Omeros seeks EMA approval for narsoplimab to treat stem cell transplant-related TA-TMA
Omeros Corporation has submitted a Marketing Authorization Application to the EMA for narsoplimab, aiming to treat TA-TMA across Europe. Learn what’s at stake.
Astellas Pharma and MRI partner to accelerate global expansion of Japanese drug discovery startups
Astellas Pharma and Mitsubishi Research Institute partner to accelerate Japan’s drug discovery startups under MEDISO, offering global access and lab support.
Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in…
Pharma breakthrough! BioIntelect to revolutionise trials using Opyl’s cutting-edge tech
In a landmark collaboration, Opyl Limited announced a new six-month agreement with BioIntelect, a renowned Clinical Research Organisation…
Thermo Fisher Scientific acquires Henogen from Novasep for €725m to expand viral vector manufacturing capabilities
Thermo Fisher Scientific has completed the acquisition of Henogen, a viral vector manufacturing business previously owned by Groupe…